结核分枝杆菌
多核苷酸磷酸化酶
肺结核
吡嗪酰胺
突变体
生物
核糖核酸
抗药性
突变
微生物学
病毒学
遗传学
酶
生物化学
医学
基因
嘌呤核苷磷酸化酶
嘌呤
病理
作者
N. Wang,Yanan Sheng,Yutong Liu,Yaoting Guo,Jiang He,Jinsong Liu
标识
DOI:10.1016/j.abb.2024.109917
摘要
As one of the oldest infectious diseases in the world, tuberculosis (TB) is the second most deadly infectious disease after COVID-19. Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), which can attack various organs of the human body. Up to now, drug-resistant TB continues to be a public health threat. Pyrazinamide (PZA) is regarded as a sterilizing drug in the treatment of TB due to its distinct ability to target Mtb persisters. Previously we demonstrated that a D67 N mutation in Mycobacterium tuberculosis polynucleotide phosphorylase (MtbPNPase, Rv2783c) confers resistance to PZA and Rv2783c is a potential target for PZA, but the mechanism leading to PZA resistance remains unclear. To gain further insight into the MtbPNPase, we determined the cryo-EM structures of apo Rv2783c, its mutant form and its complex with RNA. Our studies revealed the Rv2783c structure at atomic resolution and identified its enzymatic functional groups essential for its phosphorylase activities. We also investigated the molecular mechanisms underlying the resistance to PZA conferred by the mutation. Our research findings provide structural and functional insights enabling the development of new anti-tuberculosis drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI